Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetically prioritized druggable targets for amyloid-β pathology highlight <i>ACE</i> as a therapeutic candidate in Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

Germline APOE ε2 homozygosity and reduced risk of breast cancer: a population-based cohort study.

Breast cancer research : BCR·2026
Same author

Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer's disease.

Alzheimer's research & therapy·2026
Same author

Demographic, Social, and Clinical Profiles of Patients Initiating Lecanemab in Clinical Practice: A Single-Center Experience in Korea.

Dementia and neurocognitive disorders·2026
Same author

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Deciphering the role of endolysin LysCPD7 harboring C. perfringens spore binding domain.

Microbiological research·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Jihwan Yun1, Daeun Shin2, Eun Hye Lee2

  • 1Kyung Hee University Medical Center, Seoul, Korea, Republic of (South).

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Adjusting plasma phosphorylated tau (p-tau) 217 cutoffs for kidney function, BMI, and anemia improves Alzheimer's disease detection. Tailoring thresholds enhances diagnostic accuracy, particularly in patients with impaired kidney function.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarker Research
  • Alzheimer's Disease Diagnostics

Background:

  • Plasma phosphorylated tau (p-tau) 217 is a promising biomarker for detecting amyloid-beta (Aβ) positivity.
  • Factors like kidney dysfunction, BMI, and anemia can influence p-tau217 levels.
  • Optimal p-tau217 cutoffs require investigation across diverse physiological conditions.

Purpose of the Study:

  • To determine how optimal cutoffs for plasma p-tau217 vary with estimated glomerular filtration rate (eGFR), body mass index (BMI), and anemia.
  • To assess the impact of these factors on the diagnostic accuracy of p-tau217 for Aβ positivity.

Main Methods:

  • A multi-center study of 2,571 participants with varying cognitive statuses.
  • Plasma p-tau217 measured using Alzpath Simoa immunoassay alongside Aβ PET imaging.
  • Participants categorized by eGFR, BMI, and anemia status to identify adjusted p-tau217 cutoffs.

Main Results:

  • Elevated optimal p-tau217 cutoffs were observed in individuals with kidney dysfunction (e.g., eGFR <45), underweight, obesity, and anemia.
  • Applying a standard cutoff in the severe kidney dysfunction group (eGFR <45) reduced diagnostic accuracy to 48.3%.
  • Adjusted cutoffs improved diagnostic performance, highlighting the need for personalized thresholds.

Conclusions:

  • Tailoring plasma p-tau217 cutoffs based on kidney function, BMI, and anemia is crucial for accurate Alzheimer's disease diagnosis.
  • The diagnostic utility of p-tau217 is significantly influenced by these physiological parameters.
  • Specific adjustments are vital for populations with compromised kidney function (eGFR <45).